Sandoz launches generic Emend capsules
PRINCETON, N.J. — Sandoz on Wednesday announced the launch of its generic of Emend (aprepitant) capsules. The drug is indicated to prevent nausea and vomiting caused by certain chemotherapy medicines in patients ages 12 years and older, as well as to prevent nausea and vomiting after surgery.
“Sandoz is the first company to offer a generic of Emend capsules, which demonstrates our passion for bringing high-quality generic medicines to patients and healthcare professionals,” Sandoz president Peter Goldschmidt said.
The drug will be available in 40-, 80- and 125-mg dosage strengths. It had U.S. sales of about $62 million for the 12 months ended October 2016, according to QuintilesIMS data.
Regeneron names new SVP portfolio management
TARRYTOWN, N.Y. — Regeneron Pharmaceuticals announced Wednesday the addition of Dr. Jay Markowitz to its leadership team as its new SVP portfolio management. He joins the pharma company from Capital World Investors, where was a U.S. pharmaceutical and biotechnology analyst and portfolio manager.
“Jay is a powerful addition to our leadership team at a very important time for the company as our pipeline continues to grow and diversify," Regeneron president and chief scientific officer Dr. George Yancopoulos said. “Jay's deep scientific and medical expertise, coupled with his incredible track record as a leading biopharma portfolio manager and analyst, will help Regeneron further refine our portfolio strategy in order to bring important new medicines to patients as quickly and efficiently as possible."
Markowitz will work with other scientific and development leaders to evaluate the company’s portfolio evaluation and decision making while assessing external opportunities. Before Capital World Investors, Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before his investment career, he was an assistant professor and transplant surgeon at Johns Hopkins University School of Medicine.
"Regeneron stands out as a company with a robust, diverse pipeline and a deep productive scientific and technological engine," Markowitz said. "I am thrilled to join this great team that is advancing important and promising potential treatments for people with a number of serious diseases."
Sanofi announces U.S. availability of Soliqua 100/33
PARIS — Sanofi on Wednesday announced the U.S. availability of its Soliqua 100/33 (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL) injection pen. The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide.
Sanofi said the daily wholesale acquisition price of Soliqua 100/33 was $127 for a 300 mL pen, an average of about $19.90 per day given the average final dose of 47 mL used in clinical trials. It is also offering it at a $0 for eligible patients with commercial insurance and is working on securing coverage on nationwide health plans. It will also offer Soliqua 100/33 COACH, for patients who have been prescribed the medication.
“By offering Soliqua 100/33 – a product containing both a basal insulin and a GLP-1 therapy — at a competitive price while facilitating patient access, we believe we are providing value to patients and the healthcare system,” Sanofi EVP and head of its global diabetes and cardiovascular business unit Peter Guenter said.
Loading Post Please Wait...